Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
J Am Med Dir Assoc ; 17(10): 896-901, 2016 10 01.
Article in English | MEDLINE | ID: mdl-27262494

ABSTRACT

BACKGROUND: Our study aimed to investigate the effect of dipeptidyl peptidase 4 inhibitors (DPP4-I) on sarcopenic parameters in elderly type 2 diabetic patients. DESIGN: All elderly diabetic patients were invited to present themselves at our outpatient Geriatric Centre to undergo to evaluation of glycemic, inflammatory, and sarcopenic parameters and to perform a meal test for glucagon-like peptide-1 analogue (GLP-1) activity evaluation. SETTING: According to European Working Group on Sarcopenia in Older People (EWGSOP) criteria, sarcopenic parameters were assessed by bioelectrical impedance analysis (BIA) and Kern dynamometer and 4-m gait speed tests. All patients received standardized meals for the assessment of postprandial levels of GLP-1 activity. PARTICIPANTS, MEASUREMENTS: Data of 80 elderly diabetic patients treated with oral glucose-lowering drugs (DPP4-I or Sulfonylureas Group) for at least 24 months before enrollment were analyzed. RESULTS: The DPP4-I Group showed appropriate glycemic control, lower levels of inflammatory parameters, a significant and greater increase, during interprandial periods, of GLP-1 activity, and better sarcopenic parameters (fat-free mass, skeletal muscle mass, and related indices, muscle strength, and gait speed) compared with the Sulfonylureas Group. Univariate analysis showed that sarcopenic parameters correlated with glycemic control and with GLP-1 area under the curve values. Multivariate analysis confirms these relationships. CONCLUSION: The results are consistent with the hypothesis that DPP4-I use might have a positive effect on the loss of muscle mass and its function.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Dipeptidyl-Peptidase IV Inhibitors/pharmacology , Sarcopenia/drug therapy , Aged , Aged, 80 and over , Aging , Clinical Laboratory Techniques , Dipeptidyl-Peptidase IV Inhibitors/administration & dosage , Female , Humans , Male , Muscle Strength/physiology
2.
J Diabetes Res ; 2016: 5876792, 2016.
Article in English | MEDLINE | ID: mdl-26824045

ABSTRACT

BACKGROUND: We investigated the predictive value of morning blood pressure surge (MBPS) on the development of microalbuminuria in normotensive adults with a recent diagnosis of type 2 diabetes. METHODS: Prospective assessments of 24-hour ambulatory blood pressure monitoring and urinary albumin excretion were performed in 377 adult patients. Multivariate-adjusted Cox regression models were used to assess hazard ratios (HRs) between baseline and changes over follow-up in MBPS and the risk of microalbuminuria. The MBPS was calculated as follows: mean systolic BP during the 2 hours after awakening minus mean systolic BP during the 1 hour that included the lowest sleep BP. RESULTS: After a mean follow-up of 6.5 years, microalbuminuria developed in 102 patients. An increase in MBPB during follow-up was associated with an increased risk of microalbuminuria. Compared to individuals in the lowest tertile (-0.67 ± 1.10 mmHg), the HR and 95% CI for microalbuminuria in those in the highest tertile of change (24.86 ± 6.92 mmHg) during follow-up were 17.41 (95% CI 6.26-48.42); p for trend <0.001. Mean SD MBPS significantly increased in those who developed microalbuminuria from a mean [SD] of 10.6 [1.4] to 36.8 [7.1], p < 0.001. CONCLUSION: An increase in MBPS is associated with the risk of microalbuminuria in normotensive adult patients with type 2 diabetes.


Subject(s)
Albuminuria/etiology , Blood Pressure , Circadian Rhythm , Diabetes Mellitus, Type 2/complications , Diabetic Nephropathies/etiology , Adult , Albuminuria/diagnosis , Albuminuria/physiopathology , Blood Pressure Monitoring, Ambulatory , Chi-Square Distribution , Diabetes Mellitus, Type 2/diagnosis , Diabetes Mellitus, Type 2/physiopathology , Diabetic Nephropathies/diagnosis , Diabetic Nephropathies/physiopathology , Disease Progression , Female , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Multivariate Analysis , Proportional Hazards Models , Prospective Studies , Risk Assessment , Risk Factors , Time Factors , Wakefulness
3.
J Cardiol ; 67(2): 153-61, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26347218

ABSTRACT

BACKGROUND: Takotsubo syndrome is a stress cardiomyopathy, characterized by reversible left ventricle (LV) apical ballooning in the absence of significant angiographic coronary artery stenosis. The frequent association with emotional stress suggests in this disease an autonomic nervous system involvement. We could think that a therapeutic treatment targeting heart sympathetic dysfunction could be of crucial importance. METHODS: From January 2010 to June 2012, 886 patients were consecutively evaluated at Cardarelli Hospital, Naples, Italy. Among these, 48 patients met takotsubo cardiomyopathy (TCM) criteria. Each patient was assessed with history and physical examination, 12-lead electrocardiogram, serum troponin, coronary arteriography, and left ventricular angiogram, perfusion myocardial scintigraphy with technetium 99m, with echocardiography and 123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy. At discharge, the surviving patients were randomly assigned to α-lipoic acid (ALA) treatment (600mg once daily) or placebo. Following discharge, after the initial TCM event, patients returned to our outpatient clinic at Internal Medicine of the Second University Naples for the follow-up evaluation quarterly until 12 months. Routine analysis, myocardial damage serum markers, oxidative stress serum markers, pro-inflammatory cytokines, and sympathetic tone activity were evaluated in all patients. RESULTS: ALA administration improved MIBG defect size at 12 months compared to placebo. CONCLUSIONS: Adrenergic cardiac innervation dysfunction in TCM patients persists after previous experience of transient stress-induced cardiac dysfunction. ALA treatment improves the adrenergic cardiac innervation. This study evaluates whether sympatho-vagal alterations are TCM event-related.


Subject(s)
Heart/innervation , Sympathetic Nervous System/drug effects , Sympatholytics/therapeutic use , Takotsubo Cardiomyopathy/drug therapy , Thioctic Acid/therapeutic use , 3-Iodobenzylguanidine , Aged , Antioxidants/therapeutic use , Coronary Angiography , Cytokines/blood , Double-Blind Method , Echocardiography , Electrocardiography , Female , Heart Ventricles , Humans , Middle Aged , Myocardial Perfusion Imaging/methods , Oxidative Stress/drug effects , Postmenopause , Stress, Psychological/complications , Takotsubo Cardiomyopathy/blood , Takotsubo Cardiomyopathy/complications , Troponin/blood
4.
Epilepsy Behav Case Rep ; 4: 9-12, 2015.
Article in English | MEDLINE | ID: mdl-26101747

ABSTRACT

We report a case of a 56-year-old man affected by frontal lobe seizures who has developed bradycardia followed by asystole. The patient had a positive family history for epilepsy. In fact, the mother, brothers, and one sister had epilepsy. Furthermore, the patient's two brothers suddenly died of unspecified heart disease at the ages of 26 and 53, respectively. The patient also experienced syncope once or twice a year. Three similar epileptic seizures, without the recurrence of asystole, were registered after pacemaker implantation.

5.
BMC Cardiovasc Disord ; 14: 176, 2014 Dec 06.
Article in English | MEDLINE | ID: mdl-25480761

ABSTRACT

BACKGROUND: The purpose of this study was to investigate the impact of metabolic syndrome (MS) on outcome of catheter ablation (CA) for treatment of frequent premature ventricular contraction beats (PVCs) originating from right ventricular outflow tract (RVOT), left ventricular outflow tract (LVOT) or coronary cusps (CUSPs), in patients with normal ventricular systolic function and absence of cardiac structural disease. METHODS: In this multicentre prospective study we evaluated 90 patients with frequent PVCs originating from RVOT (n = 68), LVOT (n = 19) or CUSPs (n = 3), treated with CA. According to baseline diagnosis they were divided in patients with MS (n = 24) or without MS (n = 66). The study endpoint was a composite of recurrence of acute or delayed outflow tract ventricular arrhythmia: acute spontaneous or inducible outflow tract ventricular arrhythmia recurrence or recurrence of outflow tract PVCs in holter monitoring at follow up. RESULTS: Patients with MS compared to patients without MS showed a higher acute post-procedural recurrence of outflow tract PVCs (n = 8, 66.6%, vs. n = 6, 9.0%, p = 0.005). At a mean follow up of 35 (17-43) months survival free of recurrence of outflow tract PVCs was lower in patients with baseline MS compared to patients without MS diagnosis (log-rank test, p < 0.001). In cox regression analysis, only MS was independently associated with study endpoint (HR = 9.655 , 95% CI 3.000-31.0.68 , p < 0.001). CONCLUSIONS: MS is associated with a higher recurrence rate of outflow tract PVCs after CA in patients without structural heart disease.


Subject(s)
Catheter Ablation , Metabolic Syndrome/complications , Ventricular Premature Complexes/complications , Ventricular Premature Complexes/surgery , Humans , Prospective Studies , Recurrence , Treatment Outcome
6.
Expert Rev Cardiovasc Ther ; 12(3): 323-9, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24460120

ABSTRACT

Diabetes mellitus is a risk factor for cardiovascular and cerebrovascular events independently of other factors such as age, sex, BMI and blood pressure. Diabetes plays an important role in the pathogenesis of atrial fibrillation because it causes alterations to the autonomic nervous system. It may also be associated with an increased prevalence of asymptomatic episodes of atrial fibrillation, which cause cerebrovascular disease more often than chronic atrial fibrillation. The presence of silent cerebral ischemia doubles the risk of stroke in the general population independently of other cardiovascular risk factors; therefore, early detection of these episodes is important to determine preventive measures against the first cerebrovascular disease.


Subject(s)
Atrial Fibrillation/complications , Cerebrovascular Disorders/complications , Diabetes Complications/complications , Diabetes Mellitus/diagnosis , Stroke/complications , Animals , Atrial Fibrillation/diagnosis , Atrial Fibrillation/etiology , Cerebrovascular Disorders/etiology , Diabetes Complications/diagnosis , Humans , Risk Factors , Stroke/diagnosis , Stroke/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...